A Modified Vaccine Reduces the Rate of Large Injection Site Reactions to the Preschool Booster Dose of Diphtheria-Tetanus-Acellular Pertussis Vaccine

Scheifele, David W.; Halperin, Scott A.; J, Ochnio; Ferguson, Alexander C.; Skowronski, Danuta M.

doi:10.1097/01.inf.0000190028.96152.46

Cited by 43 publications

(18 citation statements)

References 43 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…38 Adacel (Tdap) in children 4-5.5 years old. Large local reactions had elevated n = 288 pre-immunization serology, 145 DTaP.IPV and 143 Tdap pre-immunization antibody concentrations of 1 or more diphtheria, pertussis toxin or pertactin and elevated post immunization antibody concentrations to all antigens except fimbriae.…”

Section: Diphtheria/tetanus Toxoidmentioning

confidence: 99%

“…88 A significant body of data exists showing a direct correlation between elevated pre-vaccination IgG levels and local reaction. These data are derived from studies with tetanus toxoid, 28,29,[89][90][91][92][93] diphtheria toxoid, 94-100 whole cell pertussis, 101 diphtheria/tetanus/acellular pertussis (DTaP) 38,102 and pneumococcal polysaccharide vaccine. 57,81,[103][104][105][106][107][108][109][110] Inflammatory response follows the formation of immune complexes between the circulating antibodies and the injected antigen.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Sex differences in injection site reactions with human vaccines

Cook¹

2009

Human Vaccines

View full text Add to dashboard Cite

Section: Diphtheria/tetanus Toxoidmentioning

confidence: 99%

mentioning

confidence: 99%

Sex differences in injection site reactions with human vaccines

Cook¹

2009

Human Vaccines

View full text Add to dashboard Cite

“…Unfortunately, other studies did not collect data about these events. Rates of other systemic events (like fever, rash, joint pain) were lower (less than 4% for all) than after a first dose of MMR vaccination (14-18%) [21,35], probably because MMR is a live attenuated vaccine with an all-or-nothing seroconversion following vaccination. An immune host is less likely than a nonimmune host to experience vaccine virus replication, explaining the lower rate of adverse events among recipients of the second dose compared with the first [21].…”

Section: Discussionmentioning

confidence: 77%

“…After the second dose of MMR, adverse events are (expected to be) clinically similar but much less frequent, since most recipients are already immune [21]. Despite many trials to evaluate the adverse events following the MMR booster [5,15,24,26,28,35], there is limited information from population studies.…”

Section: Introductionmentioning

confidence: 97%

Parental reports of adverse events following simultaneously given dT-IPV and MMR vaccines in healthy 9-year-old children

2010

View full text Add to dashboard Cite

In the Netherlands, children at 9 years of age receive a booster dT-IPV together with their second measles, mumps, and rubella (MMR) vaccination within the national immunization program. Safety is monitored continuously by enhanced passive surveillance. This population-based study was conducted to obtain more information on adverse events after vaccination at 9 years of age. Questionnaires on local and systemic reactions were distributed 1 and 3 weeks after vaccination, respectively, to parents of 1,250 healthy children who received their MMR and diphtheria, tetanus, and inactivated poliovirus injection (dT-IPV) vaccination as scheduled. Response to the questionnaires was 57.0% and 46.5%, respectively. Local reactions occurred in 86.5% of the children within 7 days after vaccination, more often at the dT-IPV (83.4%) than at the MMR site (32.7%). Pain was the most reported symptom (80.8% at the dT-IPV site; 29.1% at the MMR site). Systemic events occurred in 33.4% children within 7 days after vaccination, with headache as the most frequently reported (20.8%). Systemic events occurred in 20.8% children 8-21 days after vaccination. Children with local reactions at only the dT-IPV site had significantly more systemic events (19.3%) than those without local reactions (3.4%, p < 0.01). Such difference was not found for the MMR site. No serious adverse events were reported. Medical intervention was applied to 133 children (130 used analgesics and for three children the GP was consulted by phone). In conclusion, the frequency of reported local reactions is high, especially at the dT-IPV site, but all symptoms were transient. However, the use of reduced antigen content vaccines in association with the occurrence of adverse events is meaningful to explore. Furthermore, the overall rates are useful for monitoring variations in adverse events rates in the general population.

show abstract

“…Of particular safety concern was the potential for increased reactogenicity when CRM 197 or TT vaccines were given to children with high diphtheria and tetanus antibody levels from a recent diphtheria/tetanus booster, or vice versa. 8 To address these concerns a trial was undertaken in which children received MCC vaccines one month before or after, or at the same time as their scheduled diphtheria/tetanus booster. The immunogenicity data have been reported.…”

Section: Introductionmentioning

confidence: 99%

Reactogenicity of Meningococcal C Conjugate Vaccines When Administered at the Same Time as, or a Month Prior to or After, Tetanus and Diphtheria Booster Vaccinations

Southern¹,

Gelb²,

Andrews³

et al. 2006

Human Vaccines

View full text Add to dashboard Cite

Introduction: This single blind study was conducted to address safety concerns regarding coadministration of diphtheria/ tetanus (DT,Td) boosters and meningococcal C conjugate (MCC) vaccines containing diphtheria or tetanus conjugate proteins.Methods: 1754 subjects (835 preschoolers and 919 school leavers) were randomised to receive one of three MCC products a month before, after or at the same as routine DT or Td boosters. They (or their parents) completed a health diary for 10 days to record local reactions and systemic symptoms after each vaccination. The effect of antibody levels pre and post-vaccination, preexisting allergies and medication taken before and for up to ten days after vaccination on reactogenicity was assessed.Results: No relationship between prevaccination antibody levels and local reactions or systemic symptoms was found. Local reactions were more common after DT/Td than MCC vaccination and were related to post-vaccination diphtheria and tetanus antibody levels in younger children and to the post-vaccination tetanus only antibody levels in older children. Preexisting allergies were not related to reactogenicity. Use of analgesics/ antipyretic medication significantly reduced the incidence of local reactions and of some systemic symptoms. In the first three days after vaccination there was an excess of some systemic symptoms including fatigue/ malaise and headache for all ages, and crying/ irritability for younger children and nausea/ vomiting and dizziness/ faintness for older subjects. Eleven serious adverse events were reported, none of which was deemed related to vaccination.Conclusion: MCC vaccines can be given under the above schedules and safely in the presence of raised diphtheria and tetanus antibody levels without materially altering reactogenicity profiles of either vaccine.

show abstract

A Modified Vaccine Reduces the Rate of Large Injection Site Reactions to the Preschool Booster Dose of Diphtheria-Tetanus-Acellular Pertussis Vaccine

Abstract: This preschool DTaP.IPV booster vaccination caused large local reactions in 1 in 5 children, with transient discomfort. With Tdap vaccine, such reactions were significantly fewer but not eliminated. A Tdap.IPV vaccine warrants study for routine use at 4-6 years of age.

Cited by 43 publications

References 43 publications

Sex differences in injection site reactions with human vaccines

Sex differences in injection site reactions with human vaccines

Parental reports of adverse events following simultaneously given dT-IPV and MMR vaccines in healthy 9-year-old children

Reactogenicity of Meningococcal C Conjugate Vaccines When Administered at the Same Time as, or a Month Prior to or After, Tetanus and Diphtheria Booster Vaccinations

Contact Info

Product

Resources

About